Astra-Oxford shot produces immune response in older adults

COVID-19 Vaccine Could be Ready by June 2021, Says Biocon's Kiran Mazumdar-Shaw

The search for a suitable vaccine for Covid-19 has nearly come to the final stage, Dr E Venkata Rao, Principal Investigator in the Covaxin human trial and Professor in the department of Community Medicine at the Institute of Medical Sciences and SUM Hospital said on Sunday.

"The results further build the body of evidence for the safety and immunogenicity of AZD1222", the spokesman said, referring to the technical name of the vaccine.

The July results, from an earlier trial phase, showed that the vaccine increased levels of both protective neutralizing antibodies and immune T-cells that target the virus.

-The vaccine maker had applied to the DCGI on October 2 seeking permission to conduct phase 3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine.

British Health Secretary Matt Hancock said a vaccine was not yet ready, but he was preparing logistics for a possible roll out.

"We want to be ready in case everything goes perfectly but it's not my central expectation that we'll be doing that this year, but the programme is progressing well, we're not there yet", Hancock said.


"I expect that by January, some of the other vaccines could be approved like AstraZeneca's, or one of our own Indian vaccines, like the one by Bharat Biotech". Called AZD1222 or ChAdOx1 nCoV-19, the viral vector vaccine is made from a weakened version of a common cold virus that causes infections in chimpanzees.

The trials will be conducted at around 30 sites in the country.

Details of the finding are expected to be published shortly in a clinical journal, the FT said.

Blood tests carried out on a set of older participants reflect data released in July which showed the vaccine did generate "robust immune responses" in healthy adults aged 18 to 55. It did not name the publication.

As reported by The Irish Independent, managing director of Pfizer's Ireland business Paul Reid (not to be confused with HSE chief Paul Reid), has said there are strong indications that the company's experimental vaccine could be granted emergency approval at the end of next month.

The vaccine most waited for the people across the globe is in news for two unfortunate incidents.

Related:

Comments

Latest news

Jack Ma’s Ant seeks to raise $35 billion in biggest-ever IPO
This is "a homecoming for capital markets in Shanghai and Hong Kong", said existing investor John Ho, founder of Janchor Partners. Chinese financial technology giant Ant Group looks set to make the world's largest stock market debut .

Medical observation imposed for travellers from Kashgar, Xinjiang
In May, China tested the 11m-strong population of Wuhan, the city where the novel coronavirus was first identified. As of Saturday, mainland China had 85,790 confirmed coronavirus cases, the health authority said.

Taylor Swift's Folklore is first album of 2020 to sell million copies
Taylor's record with total weeks at No 1 now stands at 47, one more than Whitney's tally of 46, which she had held since 1987. It sold 1.09 million in that year. "Or the aromatic scent of white wine I occasionally spill while signing".

Venezuelan opposition leader joins family in Spain after fleeing Caracas
But he said Saturday night on social media that the decision to leave his homeland had not been "simple". Lopez's wife, Lilian Tintori, who had joined him at the residence, left for Spain that May.

OnePlus Nord N10 5G and OnePlus Nord N100 launched: Price, specifications
OnePlus Nord N10 5G price has been set at GBP 329 (roughly Rs. 32,000) for the single 6GB RAM + 128GB storage variant. OnePlus Nord N10 5G and Nord N100 have been announced as the first models in the company's OnePlus Nord N series.

Other news